Phathom Pharmaceuticals annual cash and equivalents
2018
2019
2020
2021
2022
2023
2024
2025
Phathom Pharmaceuticals Cash & Equivalents Growth & History (PHAT)
Phathom Pharmaceuticals's cash and equivalents was $130.0M for fiscal 2025.
View full Phathom Pharmaceuticals company overviewPhathom Pharmaceuticals annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $130.0M | −$167.3M | −56.28% |
| 2024 | 2024-12-31 | $297.3M | −$84.1M | −22.06% |
| 2023 | 2023-12-31 | $381.4M | $226.0M | +145.45% |
| 2022 | 2022-12-31 | $155.4M | −$27.9M | −15.21% |
| 2021 | 2021-12-31 | $183.3M | −$104.2M | −36.26% |
| 2020 | 2020-12-31 | $287.5M | $43.7M | +17.94% |
| 2019 | 2019-12-31 | $243.8M | $242.9M | +27632.08% |
| 2018 | 2018-12-31 | $879,000 | — | — |
Phathom Pharmaceuticals quarterly cash and equivalents
Q4.18
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $182.5M | $32.9M | +22.00% |
| Q1 2026 | 2026-03-31 | $180.9M | −$31.4M | −14.79% |
| Q4 2025 | 2025-12-31 | $130.0M | −$167.3M | −56.28% |
| Q3 2025 | 2025-09-30 | $135.2M | −$199.5M | −59.62% |
| Q2 2025 | 2025-06-30 | $149.6M | −$126.7M | −45.85% |
| Q1 2025 | 2025-03-31 | $212.3M | −$109.9M | −34.11% |
| Q4 2024 | 2024-12-31 | $297.3M | −$84.1M | −22.06% |
| Q3 2024 | 2024-09-30 | $334.7M | $121.0M | +56.63% |
| Q2 2024 | 2024-06-30 | $276.2M | $27.4M | +11.01% |
| Q1 2024 | 2024-03-31 | $322.2M | $192.7M | +148.68% |
| Q4 2023 | 2023-12-31 | $381.4M | $226.0M | +145.45% |
| Q3 2023 | 2023-09-30 | $213.7M | $16.8M | +8.55% |
| Q2 2023 | 2023-06-30 | $248.8M | $41.5M | +19.99% |
| Q1 2023 | 2023-03-31 | $129.6M | −$8.5M | −6.17% |
| Q4 2022 | 2022-12-31 | $155.4M | −$27.9M | −15.21% |
| Q3 2022 | 2022-09-30 | $196.8M | −$27.8M | −12.37% |
| Q2 2022 | 2022-06-30 | $207.4M | −$2.3M | −1.09% |
| Q1 2022 | 2022-03-31 | $138.1M | −$99.9M | −41.97% |
| Q4 2021 | 2021-12-31 | $183.3M | −$104.2M | −36.26% |
| Q3 2021 | 2021-09-30 | $224.6M | −$1.7M | −0.77% |
| Q2 2021 | 2021-06-30 | $209.7M | −$37.6M | −15.21% |
| Q1 2021 | 2021-03-31 | $238.0M | −$18.7M | −7.28% |
| Q4 2020 | 2020-12-31 | $287.5M | $43.7M | +17.94% |
| Q3 2020 | 2020-09-30 | $226.4M | $151.9M | +203.91% |
| Q2 2020 | 2020-06-30 | $247.3M | — | — |
| Q1 2020 | 2020-03-31 | $256.7M | — | — |
| Q4 2019 | 2019-12-31 | $243.8M | $242.9M | +27632.08% |
| Q3 2019 | 2019-09-30 | $74.5M | — | — |
| Q4 2018 | 2018-12-31 | $879,000 | — | — |
Phathom Pharmaceuticals cash and equivalents trends
Over the last five fiscal years, Phathom Pharmaceuticals's cash and equivalents decreased from $287.5M to $130.0M, a change of −$157.5M. The latest reported quarter, Q2 2026, shows $182.5M.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Phathom Pharmaceuticals source filings ↗Community posts
Phathom’s Voquezna growth narrows its quarterly loss and supports positive operating cash flow
Phathom Pharmaceuticals ($PHAT) reported third-quarter 2026 revenue of $84.7 million, up 71% from a year earlier and 14% from the preceding quarter. Cumulative Voquezna prescriptions surpassed two million, reflecting continued adoption of t ...
Phathom’s Voquezna exclusivity dispute expands with FDA consultation and another challenger
Phathom ($PHAT) said the FDA opened a public docket seeking comment on legal and regulatory questions raised by a challenge to Voquezna’s exclusivity. Comments are due by November 23. Phathom has also moved to intervene in BDR Pharmaceutica ...
